MedTrace Logo

A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects

NCT06162169 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2025-04-04

No results posted yet for this study

Summary

This is a phase I study to evaluate drug-drug interactions (DDIs) of JAB-21822 as a perpetrator combined with midazolam , rosuvastatin, and digoxin and to evaluate DDIs of JAB-21822 as a victim combined with itraconazole， rifampicin， and omeprazole in healthy subjects.

Conditions

  • Healthy Subjects

Interventions

DRUG

JAB-21822

JAB-21822 was administered orally

DRUG

Itraconazole

Itraconazole was administered orally

DRUG

Omeprazole

Omeprazole was administered orally

DRUG

Midazolam , Rosuvastatin calcium and digoxin

Midazolam , Rosuvastatin calcium and digoxin was administered orally

DRUG

Rifampicin

Rifampicin was administered orally

Sponsors & Collaborators

  • Allist Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • He Qing B.Pharm · Beijing Gaobo Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-25
Primary Completion
2024-02-20
Completion
2024-02-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06162169 on ClinicalTrials.gov